Oxygenic Hybrid Semiconducting Nanoparticles for Enhanced Photodynamic Therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29220576.
- Also identified by DOI 10.1021/acs.nanolett.7b04759.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Photodynamic nanotheranostics has shown great promise for cancer therapy; however, its therapeutic efficacy is limited due to the hypoxia of tumor microenvironment and the unfavorable bioavailability of existing photodynamic agents. We herein develop hybrid core-shell semiconducting nanoparticles (SPN-Ms) that can undergo O<sub>2</sub> evolution in hypoxic solid tumor to promote photodynamic process. Such oxygenic nanoparticles are synthesized through a one-pot surface growth reaction and have a unique multilayer structure cored and coated with semiconducting polymer nanoparticles (SPNs) and manganese dioxide (MnO<sub>2</sub>) nanosheets, respectively. The SPN core serves as both NIR fluorescence imaging and photodynamic agent, while the MnO<sub>2</sub> nanosheets act as a sacrificing component to convert H<sub>2</sub>O<sub>2</sub> to O<sub>2</sub> under hypoxic and acidic tumor microenvironment. As compared with the uncoated SPN (SPN-0), the oxygenic nanoparticles (SPN-M1) generate 2.68-fold more <sup>1</sup>O<sub>2</sub> at hypoxic and acidic conditions under NIR laser irradiation at 808 nm. Because of such an oxygen-evolution property, SPN-M1 can effectively eradicate cancer cells both in vitro and in vivo. Our study thus not only reports an in situ synthetic method to coat organic nanoparticles but also develops a tumor-microenvironment-sensitive theranostic nanoagent to overcome hypoxia for amplified therapy.
Medical subject headings
- Breast Neoplasms
- Manganese Compounds
- Oxides
- Photosensitizing Agents
- Polymers
- Quantum Dots